Quality Control/Quality Assurance

Brazil's regulatory health authority, Anvisa, plans to establish quality requirements for locally produced pharmaceutical excipients, Anvisa told BioPharm International.

A one-day sign off for batch records is considered a best practice in the industry.

Recently developed immunoassay technology platforms reduce sample volume requirements and improve cycle times.

Unnecessary analytical testing can lead to unnecessary costs.

Although FDA cannot do anything to stop drugs from being discontinued, it can do something about supply and quality problems that lead to shortages.

Harmonized regulations call for a risk-based and systematic approach to evaluating and selecting CPPs.

Leading industry collaborators outline top 10 best practices for human error reduction.

The contract provider needs to know as much as the NDA holder.

A closer look at elastomer changeout times provides one example of using industry knowledge to improve operations and cost.

The confluence of science, technology, and regulation will provide our industry with the guidance to move forward.

The author describes an equation that can be used to define the Quality relationship between a contract manufacturing organization and a client, including how to factor in both party's needs and regulatory commitments.

The authors compare the exposure risk from viable particles from the air supply in four well-established aseptic filling technologies.

A Risk-Management Case Study.

This article is the second in a two-part series on extractables and leachables.

Political leaders need to consider the impact of the biopharmaceutical industry on the economy.

In this quarter's column, highlights from the IBC Single-use Applications meeting, the PDA Single-use Workshop, and the BioProcess systems Alliance International Single-Use Summit are presented.

In a culture of quality, it is important that employees adopt this mindset, not because they have to, but because they understand the importance.

Developing a quality agreement template for single-use systems.

Overcoming limitations of volumetric techniques and detecting transparent particles.

US Pharmacopeia promotes horizontal standards and a product-class approach for quality attributes.

Industry may be its own obstacle to success in achieving the desired high-performance state.

The authors focus on operational excellence in manufacturing of biotechnology therapeutic products in the QbD paradigm.

Executive management leadership is essential in the effective implementation of QbD.

US Pharmacopeia develops and improves its class approach for ensuring quality biopharmaceuticals.

The authors present an approach for testing statistical equivalence of two stability profiles.

The authors encourage biotech manufacturers to consult PDA Technical Report No. 49 for a detailed perspective on current practices and issues in biotech cleaning validation.

An approach to reduce batch time, increase productivity, and decrease costs.

An approach to biopharmaceutical development that combines Quality by Design with a suite of visual informatics tools to reduce scale-up risks.

Apply a DoE strategy to test several formulations in parallel.

Best practices to strengthen supplier quality management.